| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:6352433 | IVR | 1200 mg/kg | 1200 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 19200 mg/kg | 19200 mg/kg | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 19200 mg/kg | 19200 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 19200 mg/kg | 19200 mg/kg | Decrease in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 19200 mg/kg | 19200 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 19200 mg/kg | 19200 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 75 mg/kg | - | No significant effects observed | - | |
| IVR | 300 mg/kg | - | No significant effects observed | - | |
| IVR | 20 mg/kg | - | No significant effects observed | - | |
| PMID:6684620 | IVR | 300 mg/kg | 300 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 300 mg/kg | 300 mg/kg | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 300 mg/kg | 300 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1200 mg/kg | 1200 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1200 mg/kg | 1200 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4800 mg/kg | 4800 mg/kg | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 4800 mg/kg | 4800 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 75 mg/kg | 75 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 19200 mg/kg | 19200 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.